| Similar Articles |
|---|
 |
The Motley Fool
August 6, 2007
Brian Lawler |
Don't Discount ViroPharma The exciting biopharma announces its second-quarter financial results. Considering that its lead drug is highly profitable and has two strong pipeline candidates in development, shares of ViroPharma don't look expensive.   |
The Motley Fool
November 3, 2006
Brian Lawler |
Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future. |
The Motley Fool
January 9, 2007
Brian Lawler |
ViroPharma's Healthy Sales Guidance The coming year looks like another strong one for the drug developer. This small-cap pharmaceutical stock is worth taking a look at just for its cheap valuation. |
The Motley Fool
April 30, 2008
Brian Lawler |
ViroPharma: Risky and Exciting Solid lead drug, meet promising pipeline candidate. |
The Motley Fool
February 28, 2008
Brian Lawler |
ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline. |
The Motley Fool
November 21, 2007
Brian Lawler |
Black Friday Bargain Stock: ViroPharma Is ViroPharma a good value right now? With competition worries out of the way, and a strong and growing cash flow, it won't take much success for value investors to be rewarded. |
The Motley Fool
March 2, 2007
Brian Lawler |
Veering ViroPharma The drugmaker announces healthier fourth-quarter financial results. But investors take note: ViroPharma's product could have a formidable competitor on the market in 2008. |
The Motley Fool
October 30, 2007
Brian Lawler |
ViroPharma Gets No Respect The drugmaker announces third-quarter results; sales of its only marketed drug, antibiotic treatment Vancocin, fell due to a higher level of wholesaler stocking. Investors, take note. |
The Motley Fool
June 13, 2007
Brian Lawler |
ViroPharma Is on Its Way ViroPharma completes preliminary enrollment in a study of one of its drug candidates. Investors, take note. |
The Motley Fool
November 24, 2010
Sean Williams |
ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags. |
The Motley Fool
September 29, 2006
Brian Lawler |
The Long Road Ahead for ViroPharma Faced with the threat of generic competition, the company focuses its efforts on a new drug. ViroPharma investors should watch intently. |
The Motley Fool
February 26, 2007
Rich Duprey |
Foolish Forecast: Getting Indigestion With ViroPharma The small-cap pharmaceutical will report its fourth-quarter 2006 financial results shortly. Investors, here is what you can expect to see. |
The Motley Fool
August 10, 2007
Brian Lawler |
ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again. |
The Motley Fool
July 9, 2008
Brian Lawler |
ViroPharma Makes Its Case Rather than taking the more traditional route, ViroPharma has taken steps to try to make it significantly harder than normal for a generic-drug maker to attack its lead drug, Vancocin. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
March 20, 2006
Rich Duprey |
ViroPharma's Generic Discount This tiny biotech looks cheap in light of sell-off over generics threat. Investors would do well to look a little closer at this promising biotech. |
The Motley Fool
September 27, 2007
Brian Lawler |
ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note. |
The Motley Fool
February 9, 2009
Brian Orelli |
ViroPharma Cut in Half ViroPharma's phase 3 drug, maribavir, failed to show an effect in reducing cytomegalovirus (CMV) disease in stem cell transplant patients, and the stock gets axed in half. |
The Motley Fool
August 5, 2009
Brian Orelli |
The Cash Cow Is Out of Milk ViroPharma has milked its antibiotic Vancocin, which it bought from Eli Lilly in 2004, pretty well, but it looks like the cash cow is finally running dry. |
The Motley Fool
May 31, 2011
Brian Orelli |
Down! Up! Which Way Will Optimer Go Next? Long-term prospects look good. |
The Motley Fool
May 29, 2009
Brian Orelli |
The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin. |
The Motley Fool
April 4, 2011
Brian Orelli |
Anti-Infective, Very Effective The FDA seems to like Optimer's new antibiotic. |
The Motley Fool
November 27, 2009
Brian Orelli |
Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first. |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
The Motley Fool
July 16, 2008
Brian Lawler |
A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
April 17, 2008
Brian Lawler |
The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver. |
The Motley Fool
October 22, 2010
Brian Orelli |
No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further. |
The Motley Fool
April 6, 2011
Brian Orelli |
Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years. |
The Motley Fool
August 31, 2011
Brian Orelli |
Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease. |
The Motley Fool
December 16, 2011
Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function. |
The Motley Fool
October 31, 2007
Brian Lawler |
The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note. |
The Motley Fool
March 30, 2006
Seth Jayson |
This Month's Losers Learn to love the losers. Sometimes, they're your best bet. ViroPharma... WorldSpace... Novell... True Religion... Sadia... Brasil Telecom... |
The Motley Fool
May 25, 2011
Brian Orelli |
Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days. |
The Motley Fool
May 12, 2011
Brian Orelli |
ViroPharma Gives It a Shot Testing a subcutaneous form of Cinryze. |
